Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

64.85 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
80 81 Next >
7 Stocks With Impressive Earnings Growth: Real or Engineered?
These growth stocks have shown impressive earnings increases but not all earnings growth is the same so investors must pay attention. 
Via InvestorPlace
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
Eli Lilly stock has been on an astounding run. In 2009 its stock sold for 27.21 a share. It closed Tuesday at 891.46, up 3,149% from 2009. 
Via Investor's Business Daily
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations. 
Via Benzinga
Obesity In Children - US Parents Face Tough Time To Access Recommended Treatment, Though Novo Nordisk's Drug Still Sees Strong Demand
U.S. parents face significant barriers to accessing intensive behavioral counseling for childhood obesity, with programs often unavailable, not covered by insurance, and requiring substantial time... 
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
This stock may not be a slam dunk, but it's looking very promising. 
Via The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
Novo Nordisk Unusual Options Activity For June 13
Via Benzinga
6 Analysts Have This To Say About Novo Nordisk
Via Benzinga
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily
Could Structure Therapeutics Become the Next Novo Nordisk?
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds. 
Via The Motley Fool
3 Best Stocks to Buy From the Fantastic 5
Although the best Fantastic 5 stocks offer much relevance and plenty of upside potential, they’re still underappreciated. 
Via InvestorPlace
Week Of June 16: What's In Store For The Markets
Lots of chairs are being removed as the music gets louder and faster. It is a great time to raise cash by harvesting some gains and selling losing positions. 
Via Talk Markets
Where Will Madrigal Pharmaceuticals Be in 3 Years?
The coast is clear for it to grow, for now. 
Via The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Want peace of mind about your investments? Consider these great stocks. 
Via The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
3 Stocks to Sell as Ozempic Surges in Popularity
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity. 
Via InvestorPlace
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
They aren't the flashiest stocks, but they get the job done. 
Via The Motley Fool
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Novo Nordisk's competition in the obesity drug market is heating up. 
Via The Motley Fool
Weight Loss Drugs: Are They Really Magic?
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs." 
Via The Motley Fool
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals. 
Via Benzinga
3 Stocks to Buy as Ozempic Surges in Popularity
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand. 
Via InvestorPlace
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... 
Via Benzinga
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way. 
Via Benzinga
7 Trending Stocks With Momentum on Their Side
Trending stocks offer an opportunity to ride momentum higher and create quick returns for daring investors. 
Via InvestorPlace
Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly is serving a market that may reach $100 billion. 
Via The Motley Fool
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors. 
Via Benzinga
Exposures Product Safety
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. 
Via The Motley Fool
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
Five mega companies may offer higher earnings and return potential with lower risk. 
Via Investor's Business Daily
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback